Press release - 24/02/2021 Supposedly "silent" mutation with serious consequences So-called silent mutations have no effect on the composition of a protein. They are therefore not considered to promote cancer. However, scientists from the German Consortium for Translational Cancer Research (DKTK), partner site Essen, now describe in a case of kidney cancer an overlooked silent mutation with a major impact on prognosis.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/supposedly-silent-mutation-serious-consequences
Press release - 24/02/2021 Disease progression in childhood cancer: Lengthening of telomeres promotes relapse Neuroblastoma can spread relentlessly or shrink spontaneously. Scientists from the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg and the National Center for Tumor Diseases (NCT) Heidelberg have shown that some malignant neuroblastomas employ a trick to avoid cell death: they use a special mechanism to lengthen the telomeres at the end of their chromosomes. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/disease-progression-childhood-cancer-lengthening-telomeres-promotes-relapse
Press release - 17/02/2021 A new piece of the HIV infection puzzle explored Researchers from EMBL and Heidelberg University Hospital combine high-resolution imaging to observe the infection process in cell nuclei, opening the door for new therapeutics.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-piece-hiv-infection-puzzle-explored
Article - 17/02/2021 Whole blood model enables development of early warning system for sepsis Sepsis is a life-threatening disease that can be treated all the more successfully the faster therapy is initiated. It is not just the infection itself that is so dangerous, but a dysregulated response of the immune system. Physicians at Ulm University Hospital have now developed an animal-free test system that can be used to research the disease and develop innovative diagnostic tools to quickly assess a patient's sepsis risk and optimise…https:////www.gesundheitsindustrie-bw.de/en/article/news/whole-blood-model-enables-development-early-warning-system-sepsis
Event - 25/02/2021 Japan’s HealthTech Market: Entry Strategies For German Startups online, Webinar https:////www.gesundheitsindustrie-bw.de/en/event/japans-healthtech-market-entry-strategies-german-startups
Event - 02/03/2021 Understanding the health data future – Deloitte Healthconnect online, Registration deadline: 28/02/2021, Workshop https:////www.gesundheitsindustrie-bw.de/en/event/understanding-health-data-future-deloitte-healthconnect
Press release - 09/02/2021 New rapid test to detect coronavirus antibodies developed An international research team involving the universities of Paraná and Tübingen has developed a rapid test that can reliably identify Covid-19 antibodies in the blood within minutes. As the researchers report in the journal ACS Sensors, the new process is based on a simple measuring principle making it easy to carry out without expensive instruments, and is therefore suitable for use at mobile testing centers or by laboratories.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-rapid-test-detect-coronavirus-antibodies-developed
Press release - 01/02/2021 Targeting a rapid market breakthrough for new vaccine production method In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
Press release - 28/01/2021 Carl Zeiss Foundation funds Interdisciplinary practice Study at Heidelberg University with the sum of approximately of 4.5 Million Euros Can interconnected digital assistance systems enhance the quality of life of people in older age? Scientists in an interdisciplinary research project at Heidelberg University are exploring this question in a representative practice study. The participating researchers want to investigate how well these technical aids can be used and what benefit they achieve.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/carl-zeiss-foundation-funds-interdisciplinary-practice-study-heidelberg-university-sum-approximately-45-million-euros
Press release - 25/01/2021 Protein anchors as a newly discovered key molecule in cancer spread and epilepsy Certain anchor proteins inhibit a key metabolic driver that plays an important role in cancer and developmental brain disorders. Scientists from the German Cancer Research Center (DKFZ) and the University of Innsbruck, together with a Europe-wide research network, discovered this molecular mechanism, which could open up new opportunities for personalized therapies for cancer and neuronal diseases. They published their results in the journal Cell.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/protein-anchors-newly-discovered-key-molecule-cancer-spread-and-epilepsy
Press release - 18/01/2021 How a protein variant could explain resistance to sleeping sickness drug A specific variant of the surface protein VSG of African trypanosomes, the causative agents of sleeping sickness, is associated with resistance to the important drug Suramin. Scientists at the German Cancer Research Center have now been able to find a possible explanation for the formation of resistance based on the crystal structure of this protein variant.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/how-protein-variant-could-explain-resistance-sleeping-sickness-drug
Event - 23/02/2021 - 26/02/2021 Digital Medicine Week 2021 onlinehttps:////www.gesundheitsindustrie-bw.de/en/event/digital-medicine-week-2021
Article - 14/01/2021 Newly discovered RNA as growth driver in liver cancer Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.https:////www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
Press release - 11/01/2021 CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-non-human-primates-during-sars-cov-2-challenge-infe
Event - 12/07/2021 - 14/07/2021 Future Insight Days online, Kongress/Symposium https:////www.gesundheitsindustrie-bw.de/en/event/future-insight-days
Event - 23/02/2021 - 25/02/2021 Life-on-Chip Conference online, Registration deadline: 17/02/2021https:////www.gesundheitsindustrie-bw.de/en/event/life-chip-conference
Funding JOINT TRANSNATIONAL CALL 2021 Funding programme, Funded by: Horizon 2020, Submission deadline: 04/03/2021 https:////www.gesundheitsindustrie-bw.de/en/database/funding/joint-transnational-call-2021
Press release - 07/01/2021 CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid. Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-bayer-join-forces-covid-19-vaccine-candidate-cvncov
Infection control - 07/01/2021 Gene accordions as potential markers for pathogenic properties Bacteria must react to changes in the environment in order to survive. This is partly done by adapting genetic material, for example by multiplying and shortening individual genome segments. The research group led by Dr. Simon Heilbronner from the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen has shown that these so-called gene accordions are frequently found in the bacterium Staphylococcus aureus.https:////www.gesundheitsindustrie-bw.de/en/article/news/gene-accordions-potential-markers-pathogenic-properties
Press release - 22/12/2020 Voluntary or compulsory? New evidence on motivation for anti-Covid-19 policies A study by the University of Konstanz shows that voluntary motivation to comply with anti-Covid-19 policies is relatively high in Germany, but can be undermined by enforcement - The consequence of this finding differs depending on the policy.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/voluntary-or-compulsory-new-evidence-motivation-anti-covid-19-policies
Press release - 09/12/2020 Combatting cancer with biological circuits The Freiburg engineer and biologist Prof. Dr. Barbara Di Ventura receives a Consolidator Grant from the European Research Council (ERC), one of the most prestigious prizes for European researchers, for her project "InCanTeSiMo - Intelligent cancer therapy with synthetic biology methods". Di Ventura will use the 2 Million Euros to develop a novel cancer treatment based on molecular methods from synthetic biology.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/combatting-cancer-biological-circuits
Funding INNO4COV-19 Project Funding programme, Funded by: Horizon 2020, Submission deadline: 31/03/2021 https:////www.gesundheitsindustrie-bw.de/en/database/funding/inno4cov-19-project
Digitalisation in Medicine - 08/12/2020 DiHeSys takes steps towards application Digital Health Systems GmbH (DiHeSys) has completed its founding phase and entered a new stage of development. This is reflected in the arrival of a new managing director, a strategic cooperation and its first pilot projects.https:////www.gesundheitsindustrie-bw.de/en/article/news/dihesys-takes-steps-towards-application
Press release - 07/12/2020 One for all AI-based evaluation of medical imaging data usually requires a specially developed algorithm for each task. Scientists from the German Cancer Research Center (DKFZ) have now presented a new method for configuring self-learning algorithms for a large number of different imaging datasets – without the need for specialist knowledge or very significant computing power.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/one-all
Development of the genomDE genome database - 04/12/2020 Whole genome sequencing for diagnosing rare diseases Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…https:////www.gesundheitsindustrie-bw.de/en/article/news/whole-genome-sequencing-diagnosing-rare-diseases